Jardiance

Type 2 DM as monotherapy in adults & childn ≥10 yr inadequately controlled by diet & exercise alone & for whom metformin is inappropriate due to intolerance; as add-on combination therapy w/ other glucose-lowering medicinal products (eg, insulin) & when diet & exercise are inadequate. Reduction of CV death risk in adults w/ type 2 DM & established CV disease. Reduction of CV death & hospitalization risk for heart failure in adults w/ heart failure (NYHA class II-IV). CKD in adults.

Monotherapy & add-on combination therapy Initially 10 mg once daily, may be increased to max: 25 mg once daily if tolerated. Heart failure & CKD 10 mg once daily.

May be taken with or without food: Swallow whole w/ water.

Hypersensitivity.

Not to be used in type 1 diabetes or diabetic ketoacidosis. Discontinue use if ketoacidosis, necrotizing perineum fasciitis (Fournier's gangrene) are suspected. Patients w/ very low carbohydrate diet, acute illness, pancreatic disorders suggesting insulin deficiency, insulin dose reduction, alcohol abuse, severe dehydration & history of ketoacidosis. Vol-depletion risk in patients w/ CV disease, on antihypertensive therapy w/ history of hypotension; conditions leading to fluid loss eg, GI illness; complicated UTI eg, pyelonephritis or urosepsis; +ve glucose urine test. Assess renal function prior to & periodically during treatment. Monitor ketones in situations predisposing ketoacidosis eg, prolonged fasting due to acute illness or surgery. Counsel patients on routine preventive foot-care. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Not recommended to be initiated in renal impairment (eGFR <20 mL/min/1.73 m²) & severe hepatic impairment. Hepatic injury. Not recommended during 2nd & 3rd trimesters of pregnancy. Not to be used during lactation. Childn <10 yr w/ type 2 DM; <18 yr w/ heart failure & CKD. Elderly ≥75 yr.

Hypoglycaemia; vol depletion. Vag moniliasis, vulvovaginitis, balanitis, other genital infection, UTI eg, pyelonephritis & urosepsis; thirst; constipation; generalised pruritus, allergic skin reactions eg, rash, urticaria; increased urination; increased serum lipids.

Increased risk of dehydration & hypotension w/ thiazide & loop diuretics. Increased risk of hypoglycaemia w/ insulin & insulin secretagogues eg, sulphonylureas. Decreased blood lithium levels. Decreased efficacy w/ UGT inducers. Interference w/ 1,5-anhydroglucitol assay.

Antidiabetic Agents

A10BK03 - empagliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.

B